New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
08:20 EDTEWEdwards Lifesciences reports positive data on Sapien 3 valve
Edwards Lifesciences announced that the first data on its most advanced commercially available transcatheter aortic heart valve, the Edwards SAPIEN 3 valve, were presented in a late-breaking clinical trial session at EuroPCR 2014 by John Webb, director of interventional cardiology and cardiac catheterization laboratories at St. Paul's Hospital, Vancouver, and professor of cardiology at the University of British Columbia. The presentation concluded that outcomes at 30 days were excellent. Transfemoral SAPIEN 3 implantation was associated with a very low mortality of 2.1%, a stroke rate of 1.0%, and very few access-site complications.
News For EW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
08:07 EDTEWEdwards Lifesciences price target raised to $155 from $135 at JMP Securities
Subscribe for More Information
07:36 EDTEWEdwards Lifesciences TAVI growth reinforces bullish stance, says Canaccord
Subscribe for More Information
07:07 EDTEWEdwards price target raised to $151-$152 from $135-$140 at Wells Fargo
Wells Fargo increased its price target on Edwards Lifesciences as the firm believes that the company's roughly in-line 2015 guidance announced yesterday is conservative.The firm also notes that the company raised its long-term TAVR market assumption to over $3B in 2019. The firm keeps an Outperform rating on the shares.
December 8, 2014
08:16 EDTEWEdwards Lifesciences announces investments in CardioKinetix
Edwards made a structured investment in CardioKinetix, a privately held medical device company pioneering a catheter-based treatment for heart failure. This transaction increases Edwards' existing minority interest in CardioKinetix and provides an option to purchase the remaining outstanding shares for a future payment, plus additional milestone payments based on future regulatory and reimbursement approvals. In the second investment, the company acquired intellectual property that broadens its transcatheter mitral valve development efforts. Additional details of both investments were not disclosed.
08:15 EDTEWEdwards Lifesciences sees FY15 EPS $3.90-$4.10, consensus $3.96
Subscribe for More Information
08:12 EDTEWEdwards Lifesciences backs FY14 EPS $3.33-$3.39, consensus $3.39
Subscribe for More Information
06:05 EDTEWEdwards Lifesciences to host investor meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use